Sunshine Lake Pharma’s Olorigliflozin Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 10:38 AM06887-0.49%
Yushuai Zhang Bought 3.8% More Shares In Sunshine Lake PharmaSimplywall·Nov 13, 2026 at 10:24 PM06887-0.49%
Chongqing Machinery Sells an Auto Unit as Sunshine Lake Pivots to InsulinGlobal Report·Oct 21, 2026 at 10:49 AM02722-3.38%06887-0.49%
Sunshine Lake Pharma Wins China Nod for Dual-Action Insulin, Expands Global FootprintTip Ranks·Oct 8, 2026 at 11:11 AM06887-0.49%
For Hong Kong's Overlooked Names, 2026 Is an Access Story, Not an Earnings StoryGlobal Report·Oct 7, 2026 at 10:53 AM03698-0.95%80700-1.44%
Cigarette Giants and Formula Leaders Reshape Hong Kong's Fringe StocksGlobal Report·Oct 7, 2026 at 09:16 AM06055-2.63%06186+0.18%
Unpacking the Micro Signals from Hong Kong's Fringe Equities in H1 2026Global Report·Sep 8, 2026 at 11:33 AM08527-2.94%82020-0.21%
HK Niche Shuffle: Sinopharm Divests Assets as SY Holdings ExpandsGlobal Report·Sep 8, 2026 at 09:19 AM01099+0.36%06069+1.02%
Sunshine Lake Pharma (SEHK:6887) Stock Trails Fragile Profits And Valuation DoubtsSimplywall·Sep 1, 2026 at 12:26 PM06887-0.49%
Sunshine Lake Pharma Co: Revenue fell sharply and losses widened as core influenza drug sales declined, despite R&D and global expansionQuartr·Aug 31, 2026 at 09:07 AM06887-0.49%
Sunshine Lake Pharma sets board meeting to review interim results, consider dividendPUBT·Aug 19, 2026 at 08:35 AM06887-0.49%600673+2.00%
The Hong Kong Market's Long Tail: Aggregation, Value Chains, and Idiosyncratic Business ModelsGlobal Report·Aug 14, 2026 at 09:46 AM06887-0.49%02603-2.21%
China's Volume‑Based Procurement System Drives Domestic Insulin Supplier to Go GlobalYicai·Aug 14, 2026 at 08:52 AM06887-0.49%603707+0.72%
Sunshine Lake Pharma Ships First Interchangeable Insulin Glargine to U.S.Tip Ranks·Jul 31, 2026 at 10:42 AM06887-0.49%